A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I InhibitorsTona M. Gilmer, Michael B. Kastan, Chun-Hsiang Lai et al.|Molecular Cancer Therapeutics|2024Cited by 30
Abstract LB181: First disclosure of XRD-0394, a novel dual ATM/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitorsTona M. Gilmer, Michael B. Kastan, Chun-Hsiang Lai et al.|Cancer Research|2024Cited by 4
Pathway Coessentiality Mapping Reveals Complex II is Required for <i>de novo</i> Purine Biosynthesis in Acute Myeloid LeukemiaAmy E. Stewart, Matthew D. Hirschey, Derek K. Zachman et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 2
Pathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemiaAmy E. Stewart, Matthew D. Hirschey, John Bradley et al.|Nature Metabolism|2025Cited by 2
Kinase Panel 2 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I InhibitorsTona M. Gilmer, Michael B. Kastan, Chun-Hsiang Lai et al.|Unknown|2024Cited by 0